| 摘要: |
| 目的 探索附加倍他司汀对接受奥氮平治疗的男性精神分裂症患者体重和脂代谢的影
响。方法 选取 2020 年 9 月至 2021 年 9 月在北京回龙观医院住院的 41 例男性精神分裂症患者为研究
对象。在单药使用奥氮平治疗≥ 3 个月的基础上，附加倍他司汀 16 mg，3 次 /d，进行为期 4 周的开放性
试验。分别于基线期和治疗 4 周末取晨起空腹静脉血测血常规、空腹血糖、甘油三酯、总胆固醇、肝功
能等指标，同一时间测量患者晨起空腹体重、身高、腹围和血压，并计算体重指数（BMI）。采用阳性和阴
性症状量表（PANSS）评估患者治疗前和治疗4周末的精神疾病症状的严重程度。采用配对t检验对治疗
前后各指标进行统计分析。结果 附加倍他司汀治疗4周后，患者体重［（70.1±6.7）kg比（71.7±7.5）kg］、
BMI ［（24.7±2.1）kg/m2
比（25.2±2.4）kg/m2
］、总胆固醇水平［（4.3±0.8）mmol/L 比（4.6±0.8）mmol/L］低于
治疗前，差异有统计学意义（t=4.52、3.97、2.47； P＜ 0.05）。附加倍他司汀治疗前后，患者 PANSS 总分、
血常规指标、谷丙转氨酶比较，差异无统计学意义（P＞ 0.05）。结论 附加倍他司汀治疗对男性精神分
裂症患者奥氮平相关的体重增加和胆固醇升高具有改善作用。 |
| 关键词: 精神分裂症 倍他司汀 奥氮平 体重 脂代谢 |
| DOI：10.3969/j.issn.1009-6574.2022.06.005 |
|
| 基金项目:北京市科技计划项目（D171100007017002）；北京回龙观医院“龙跃”计划项目（2014LYJQ-2） |
|
| An open-ended study： effects of betahistine therapy on body weight and lipid metabolism in olanzapine-treated male schizophrenia |
| Bai Luyuan,Yang Fude,Zhang Xiaolu,Liu Xiaolei,Zhou Chenhui,Wang Yongqian,Wang Zhiren |
| () |
| Abstract: |
| Objective To preliminarily explore the possible effect of betahistine on body weight and
lipid metabolism in male schizophrenics treated with olanzapine. Methods A total of 41 male patients with
schizophrenics hospitalized in Beijing Huilongguan Hospital from September 2020 to September 2021 were
selected. A 4-week open-ended trail were carried out with additional betahistine 16 mg， 3 times per day， based
on single drug treatment with olanzapine for 4 months and over. Fasting full blood examination， fasting blood
sugar， triglyceride， total cholesterol， liver function and other indicators were tested at baseline and the end of
4 weeks' treatment. At the same time， fasting weight， height， abdominal circumference， and blood pressure
were measured， and body mass index （BMI） were calculated. Clinical symptoms were assessed at baseline and over 4 weeks using the Positive and Negative Symptom Scale （PANSS）. The results of each index before and after
the test were statistically analyzed by paired-sample t test. Results After 4 weeks of betahistine intervention，
patients' body weight ［（70.1±6.7） kg vs （71.7±7.5） kg］， BMI ［（24.7±2.1） kg/m2
vs （25.2±2.4） kg/m2
］， and
total cholesterol ［（4.3±0.8） mmol/L vs （4.6±0.8） mmol/L］ were all lower than those before treatment， and the
differences were statistically significant （t=4.52，3.97，2.47； P＜ 0.05）. There was no significant difference in
PANSS total score， blood routine index and alanine aminotransferase before and after treatment with betahistine
（P ＞ 0.05）. Conclusions Betahistine may improve the body weight and cholesterol of male patients with
schizophrenia caused by olanzapine. |
| Key words: Schizophrenia Betahistine Olanzapine Weight Lipid metabolism |
